GMGang Ma

Gang Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gang Ma has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Fenglin Cai

    Department of Biochemistry and Molecular Biology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, PR China

    5 shared publications
  • Jingyu Deng

    Tianjin Medical University Cancer Institute and Hospital

    4 shared publications
  • Rupeng Zhang

    Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, PR China

    4 shared publications
  • Bin Ke

    Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060, China

    3 shared publications
  • Han Liang

    Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin’s Clinical Research Center for Cancer

    3 shared publications
  • Jingyu Deng

    Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Gastr Surg, Tianjin, Peoples R China

    3 shared publications

Latest Publications

  • UBL3 modification reduces nuclear POLE levels to potentiate antitumor immunity in aero-upper digestive squamous cell carcinomas

    by Zhonglan Dong, Wenbai Huang, Lei Zhang, Qianru Guo, Xiaobei Zhang, Yang Yang, Xudong Wang, Zhihua Liu, Yiqing Yin, Gang Ma

  • Open Access

    Pan-cancer landscape of ITGAV and its potential role in gastric cancer

    by Bin Ke, Peng Jin, Xue-Jun Wang, Ru-Peng Zhang, Ning Liu, Gang Ma

    Integrin subunit alpha V (ITGAV), a subunit of the integrin receptor, is involved in many types of cancers. In order to explore the potential mechanisms of ITGAV in cancers, we carried out a comprehensive pan-cancer analysis using public database. In this study, ITGAV expression in different cancers and the relationship between ITGAV and clinic-pathological features, prognosis, genetic alteration, epigenetic modification, and tumor immune microenvironment were systemically analyzed. Gene enrichment analysis was performed to explore potential functions of ITGAV in gastric cancer (GC). GC tissue microarrays and in vitro cell experiments were used to verify the prediction results in GC. The results revealed that ITGAV was variably expression in different cancers, and ITGAV had a certain prognostic and diagnostic value in most cancers, including GC. ITGAV expression was found to be related to genetic alteration, DNA methylation, immune checkpoint gene, and immune cell infiltration in multiple cancers. Functional analyses revealed that ITGAV was involved in the regulation of EMC remodeling, ferroptosis, and cuproptosis in GC. In vitro experiments verified that ITGAV was correlated with GC cell proliferation, apoptosis, migration, and invasion. Our study demonstrated that ITGAV can be used as an effective prognostic and immunological biomarker for multiple cancers. ITGAV can promote GC malignant progression and could serve as a potential therapeutic target for GC treatment.


  • Open Access

    ACAT2 suppresses the ubiquitination of YAP1 to enhance the proliferation and metastasis ability of gastric cancer via the upregulation of SETD7

    by Mengmeng Zhang, Fenglin Cai, Jiamei Guo, Siya Liu, Gang Ma, Mingzhi Cai, Rupeng Zhang, Jingyu Deng

    The contributions of aberrantly expressed metabolic enzymes to gastric cancer (GC) initiation and progression have been widely appreciated in recent years. Acetyl-CoA acetyltransferase 2 (ACAT2) is one member of the acetyl- CoA thiolase family. Previous studies demonstrated that ACAT2 either promotes or suppresses tumor progression in different conditions. However, the function and mechanisms of ACAT2 in GC remain unknown. We found that the expression of this enzyme was significantly increased in GC tissues compared with normal counterparts, which prompted us to further investigate the roles of this protein in GC biology. In vitro functional studies showed that ACAT2 knockdown markedly halted the proliferation and the motility of GC cells; these functions favoring malignant phenotypes of GC cells were further validated in animal experiments. Mechanistically, ACAT2 depletion significantly reduced the transcription of SETD7, which is a histone methyltransferase and plays critical roles in GC cells. We found that the pro-tumoral functions of ACAT2 were largely dependent on SETD7. Moreover, SETD7 decreased the ubiquitination level of Yes-associated protein 1 (YAP1), thereby protecting YAP1 from proteasome degradation. Increased YAP1 protein expression remarkably activated the YAP1/TAZ-TEAD1 signaling pathway, which further boosted the malignant phenotypes in GC cells. In conclusion, these findings highlight the pro-tumoral functions and molecular underpinnings of ACAT2 in GC cells, and suggest that ACAT2 could be a promising target in GC treatment.


  • Ketohexokinase-A deficiency attenuates the proliferation via reducing β-catenin in gastric cancer cells

    by Gang Ma, Siya Liu, Fenglin Cai, Han Liang, Jingyu Deng, Rupeng Zhang, Mingzhi Cai


  • EGLN3 attenuates gastric cancer cell malignant characteristics by inhibiting JMJD8/NF-κB signalling activation independent of hydroxylase activity

    by Fenglin Cai, Xiuding Yang, Gang Ma, Pengliang Wang, Mengmeng Zhang, Nannan Zhang, Rupeng Zhang, Han Liang, Yongzhan Nie, Cheng Dong, et al.

    Background The expression of Egl-9 family hypoxia-inducible factor 3 (EGLN3) is notably decreased in various malignancies, including gastric cancer (GC). While the predominant focus has been on the hydroxylase activity of EGLN3 for its antitumour effects, recent findings have suggested nonenzymatic roles for EGLN3. Methods This study assessed the clinical significance of EGLN3 expression in GC and explored the connection between EGLN3 DNA promoter methylation and transcriptional silencing. To investigate the effect of EGLN3 on GC cells, a gain-of-function strategy was adopted. RNA sequencing was conducted to identify the key effector molecules and signalling pathways associated with EGLN3. Results EGLN3 expression was significantly reduced in GC tissues, correlating with poorer patient prognosis. EGLN3 hypermethylation disrupts transcriptional equilibrium, contributing to deeper tumour invasion and lymph node metastasis, thus exacerbating GC progression. Conversely, restoration of EGLN3 expression in GC cells substantially inhibited cell proliferation and metastasis. EGLN3 was also found to impede the malignant progression of GC cells by downregulating Jumonji C domain-containing protein 8-mediated activation of the NF-κB pathway, independent of its hydroxylase activity. Conclusions EGLN3 has the potential to hinder the spread of GC cells through a nonenzymatic mechanism, thereby shedding light on the complex nature of GC progression.


  • Open Access

    SCAMP1 silencing inhibits proliferation by attenuating multiple pro-survival signaling pathways in gastric cancer

    by Gang Ma, Yang Yang, Fenglin Cai, Bin Ke, Jingyu Deng

    Secretory carrier-associated membrane protein 1 (SCAMP1) is the most universally expressed member of the SCAMP family, and its ability to facilitate endocytosis was demonstrated approximately two decades ago. Nevertheless, its roles in cancer biology are largely unknown, although its expression is significantly increased in most cancer types. Herein, we examined the expression of SCAMP1 in gastric cancer (GC) tissues and found that it was aberrantly increased and positively correlated with tumor size and lymph node metastasis. More importantly, increased SCAMP1 expression was associated with poor prognosis in patients with GC. Functional experiments demonstrated that SCAMP1 knockdown markedly suppressed the proliferation of GC cells in vitro and in vivo. RNA sequencing assays demonstrated that SCAMP1 knockdown altered the expression profile of GC cells, and a significant portion of the altered genes were enriched in receptor tyrosine kinases and their related downstream signaling pathways. Immunoblotting confirmed that the Akt/MAPK/Stat signaling pathway was strongly attenuated in GC cells with SCAMP1 depletion. Taken together, these results demonstrated that SCAMP1 drives hyperproliferation in GC cells, thus suggesting that further investigation into the mechanisms and translational value of SCAMP1 in treating patients with GC is warranted.


  • Open Access

    Drug-tolerant persister cancer cells

    by Pengliang Wang, Bin Ke, Gang Ma


  • Open Access

    SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner

    by Yi Zeng, Gang Ma, Fenglin Cai, Pengliang Wang, Han Liang, Rupeng Zhang, Jingyu Deng, Yong Liu

    Protein lysine methyltransferase SET and MYND domain-containing 3 (SMYD3) is aberrantly expressed in various cancer settings. The mechanisms that SMYD3 activates the expression of critical pro-tumoral genes in an H3K4me3-dependent manner have been well described in previous reports. Besides H3K4me3, H4K20me3 is another catalytic product of SMYD3, however it is a transcriptionally repressive hallmark. Since it is not clear that how SMYD3-elicited transcriptionally repressive program functions in cancer, we used gastric cancer (GC) as a model to investigate the roles of SMYD3-H4K20me3. Herein, online bioinformatics tools, quantitative PCR, western blotting and immunohistochemistry assays demonstrated that SMYD3 expression was markedly increased in GC tissues from our institutional and The Cancer Genome Atlas (TCGA) cohort. Additionally, aberrantly increased SMYD3 expression was closely associated with aggressive clinical characteristics and poor prognosis. Depletion of endogenous SMYD3 expression using shRNAs significantly attenuates the proliferation in GC cells and Akt signaling pathway in vitro and in vivo. Mechanistically, chromatin immunoprecipitation (ChIP) assay showed that SMYD3 epigenetically repressed the expression of epithelial membrane protein 1 (EMP1) in an H4K20me3-dependent manner. Gain-of-function and rescue experiments validated that EMP1 inhibited the propagation of GC cells and reduced p-Akt (S473) level. Based on these data, pharmaceutical inhibition of SMYD3 activity using the small inhibitor BCI-121 deactivated Akt signaling pathway in GC cells and further impaired the cellular viability in vitro and in vivo. Together, these results demonstrate that SMYD3 promotes the proliferation in GC cells and may be a valid target for therapeutic intervention of patients with GC.


  • DEPTOR as a novel prognostic marker inhibits the proliferation via deactivating mTOR signaling pathway in gastric cancer cells

    by Gang Ma, Yi Sun, Fenglin Cai, Mengmeng Zhang, Han Liang, Jingyu Deng, Rupeng Zhang, Li Zhang


  • Open Access

    Cysteine dioxygenase 1 attenuates the proliferation via inducing oxidative stress and integrated stress response in gastric cancer cells

    by Gang Ma, Zhenzhen Zhao, Yang Qu, Fenglin Cai, Siya Liu, Han Liang, Rupeng Zhang, Jingyu Deng

    Whereas cysteine dioxygenase 1 (CDO1) expression is lost due to its hypermethylated promoter across a range of cancer types including gastric cancer (GC), its functions and molecular underpinnings remain largely unknown. Here we demonstrate that reduced CDO1 expression is indicative of unfavorable prognosis in patients with GC. CDO1 overexpression in GC cells markedly inhibits cellular proliferation in vitro and in vivo. Mechanistically, CDO1 exerts this cytostatic effect via increasing oxidative stress and thus activating integrated stress response (ISR) in GC cells. High throughput screening (HTS) of antioxidants library identifies that Engeletin, a flavanonol glycoside, blunts oxidative stress and the ISR to relieve the inhibitory effect of CDO1 on the proliferation in GC cells. Additionally, genetic disruption or pharmaceutical inhibition of the ISR boosts the growth in the GC cells with CDO1 expression. Our data uncover the molecular mechanisms underlying the cytostatic function of CDO1 in the proliferation of GC cells.